BioSpace News Archive

British Virgin Island headquartered Lytus Technologies Holdings Private Limited (Lytus), a technology-platforms company that offers streaming and telemedicine services with business operations in the United States and India, has signed a strategic business cooperation agreement with Singapore based True Healthcare Pte Limited (True Health).

Stryker announced that it has priced an offering of $600 million aggregate principal amount of its 0.600% Notes due 2023.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully completed a A$29.6 million a private placement of ordinary shares to professional and institutional investors (Placement).

For the past 20 years, global healthcare manufacturer’s HALYARD-branded product line of masks and N95 respirators has ranked at the top of the facial protection market

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial.

Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the upsizing and pricing of an offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029 (the “Notes”)

Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference,

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the equivalent of $65 million financing and has initiated and enrolled the first patient in a Phase II registration study for CNCT19 (CD19 CAR-T)

Berkeley Lights, Inc., a leader in Digital Cell Biology, announced the pricing of its previously announced public offering of 3,000,000 shares of common stock to be sold by certain selling stockholders of Berkeley Lights at a public offering price of $86.00 per share.